Table 3.
CTC Grade 3 and 4 adverse events that occurred during the course of adjuvant TMZ that was administered after radiotherapy
| Adverse event | ≥ 65 (n = 22) | < 65 (n = 45) | p value | |||
|---|---|---|---|---|---|---|
| N | % | N | % | |||
| Hematologic | Leukocytopenia | 1 | 5 | 9 (2) | 20 (4) | 0.15 |
| Neutropenia | 1 | 5 | 2 | 4 | 1.0 | |
| Lymphocytopenia | 6 (2) | 27 (5) | 18 (2) | 40 (4) | 0.42 | |
| Thrombocytopenia | 1 | 5 | 2 (2) | 4 (4) | 1.0 | |
| Overall Grade 3/4 | 8 | 36 | 20 | 44 | 0.6 | |
| Overall Grade 4 | 2 | 9 | 3 | 7 | 1.0 | |
| Treatment-related nonhematologic | Nausea | 0 | 0 | 1 | 2 | 1.0 |
| Anorexia | 0 | 0 | 1 | 2 | 1.0 | |
| Fatigue | 1 | 5 | 0 | 0 | 0.33 | |
| Pneumonia | 3 | 14 | 2 | 4 | 0.32 | |
| Liver enzyme | 2 | 9 | 4 | 9 | 1.0 | |
| Rash | 1 | 5 | 2 | 4 | 1.0 | |
| DVT/PE | 0 | 0 | 1 | 2 | 1.0 | |
| Cognitive dysfunction | 1 | 5 | 0 | 0 | 0.33 | |
| Viral infection | 0 | 0 | 2 | 4 | 1.0 | |
| Overall Grade 3/4 | 8 | 36 | 10 | 22 | 0.25 | |
Figures in parentheses show the number or percentage of Grade 4 adverse events. CTC: common toxicity criteria, DVT: deep vein thrombosis, PE: pulmonary embolism, TMZ: temozolomide.